Press releaseGlobe Newswire
Kalaris Therapeutics
KLRS · NASDAQ
$2.07+$0.16 (+8.38%)TodayMarket closed ·
Prev close $1.91
Latest news
- Press releaseGlobe Newswire
Kalaris Expands Leadership Team Appointing Liisa Bayko as Chief Financial Officer
- NewsVandana Singh
Why Is Kalaris Therapeutics Stock Gaining Friday?
- News
12 Health Care Stocks Moving In Friday's Intraday Session
- Press releaseGlobe Newswire
Kalaris Therapeutics Reports Positive TH103 Phase 1a SAD Results from Expanded Neovascular AMD Cohorts
- Press releaseGlobe Newswire
Kalaris Reports First Quarter 2026 Financial Results and Provides Business Updates
- Press releaseGlobe Newswire
Kalaris Reports Full Year 2025 Financial Results and Provides Business Updates
- News
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
- Press releaseGlobe Newswire
Kalaris Therapeutics Announces Oversubscribed $50.0 Million Private Placement
- Press releaseGlobe Newswire
Kalaris Therapeutics Reports Positive Initial Phase 1a Data for TH103 in Treatment-Naïve Neovascular AMD
- News
12 Health Care Stocks Moving In Tuesday's Intraday Session
- News
12 Health Care Stocks Moving In Wednesday's After-Market Session
- Press releaseGlobe Newswire
Kalaris Reports Third Quarter 2025 Financial Results and Provides Business Updates
- Press releaseGlobe Newswire
Kalaris Expands Leadership Team Appointing Matthew Gall, MBA, as Chief Financial Officer
- Press releaseGlobe Newswire
UPDATE – Kalaris Therapeutics Now Enrolling Phase 1b/2 Multiple Ascending Dose Study of TH103 in Neovascular Age-Related Macular Degeneration
- News
12 Health Care Stocks Moving In Wednesday's After-Market Session
- NewsAvi Kapoor
Why Snowflake Shares Are Trading Higher By 14%; Here Are 20 Stocks Moving Premarket
- News
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
- News
12 Health Care Stocks Moving In Friday's Pre-Market Session
- Press releaseGlobe Newswire
Kalaris Reports First Quarter 2025 Financial Results and Provides Business Highlights
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.